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Approximately 30% of all hereditary diffuse gastric cancer (HDGC) families carry CDH1 germline mutations. The other two
thirds remain genetically unexplained and are probably caused by alterations in other genes. Using polymerase chain reaction
(PCR)/single-strand conformation polymorphism (SSCP)/sequencing, we screened 32 Portuguese families with a history of gastric
cancer and 23 patients with early onset gastric cancer for CDH1 germline mutations. In probands negative for CDH1 mutations, we
screened genes involved in hereditary cancer syndromes in which gastric cancer may be one of the component tumours, namely p53
(Li-Fraumeni Syndrome) and hMLH1 and hMSH2 (HNPCC). We also screened in these patients for mutations in Caspase-10, a
gene inactivated in sporadic gastric cancer, and SMAD4, a gene whose inactivation in mice is associated with signet-ring cell
carcinoma of the stomach. One of the families fulfilling the HDGC criteria harboured a CDH1 germline mutation, and one of the
families with incomplete criteria harboured a p53 germline mutation. No mutations were identified in hMLH1 and hMSH2, and
only sequence variants were found in SMAD4 and Caspase-10. The present work reports for the first time CDH1 germline mutations
in Portuguese gastric cancer families, and highlights the need for p53 mutation screening in families lacking CDH1 germline mu-
tations, in a country with one of the highest incidences of gastric cancer in the world. No evidence was found for a role of germline
mutations in SMAD4 and Caspase-10 in families lacking CDH1 mutations.
 2004 Elsevier Ltd. All rights reserved.
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The incidence of gastric cancer has been decreasing
in older patients, but in younger patients and cases
with familial clustering the level remains stable [1].
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served in approximately 10% of the cases [2,3], but only
1–3% of gastric carcinomas arise as a result of inherited
gastric cancer predisposition syndromes [4].
In 1999, clinical criteria for the hereditary diffuse
gastric cancer (HDGC) syndrome were defined by the
International Gastric Cancer Linkage Consortium (IG-
CLC) [5]. However, gastric cancer may also be seen as
part of the tumour spectrum in other inherited cancer
predisposition syndromes, such as: hereditary non-
polyposis colorectal cancer syndrome (HNPCC), Li-
Fraumeni syndrome (LFS), Familial Adenomatous
Polyposis (FAP), Cowden syndrome and Peutz-Jeghers
syndrome (PJS) [6–10].
The presence of germline CDH1 mutations in af-
fected family members was shown to be, the genetic
defect responsible for a proportion of families with
HDGC as first described by Guilford and collaborators
in 1998 [11]. Approximately one third of families with
an aggregation of gastric cancer, fulfilling the IGCLC
criteria for HDGC studied so far, show germline CDH1
mutations in affected individuals (reviewed in [12]).
Most of these families carry truncating mutations,
whereas a small percentage carry missense mutations
[12].
Approximately two thirds of HDGC families remain
genetically unexplained. In kindred negative for CDH1
germline mutations, other genes are probably involved.
In some inherited predisposition syndromes character-
ised by a higher incidence of gastric cancer, germline
mutations of different tumour-related genes have been
demonstrated to segregate with the disease. HNPCC
occurs due to inactivating alterations of mismatch repair
genes (MMR) leading to instability at short tandem
repeat sequences – microsatellites – microsatellite in-
stability (MSI), a typical molecular manifestation of
MMR deficiency in the tumour tissue of HNPCC pa-
tients [13]. In approximately 70% of Li-Fraumeni kin-
dred, which occasionally present with gastric cancer
cases, germline mutations in p53 are found [14]. SMAD4
has been found to be inactivated in a percentage of PJS,
and knockout studies revealed the presence of foci of
signet-ring carcinoma cells in the stomach of SMAD4
heterozygous mice [15]. Each of the aforementioned
genes, as well as genes found to be inactivated in spo-
radic gastric cancer (like Caspase-10 [16]), remain good
candidates for familial gastric cancer.
We have selected a series of Portuguese families with
a positive history of gastric cancer ðn ¼ 32Þ, and a series
of Portuguese early onset gastric cancer patients
ðn ¼ 23Þ and screened all probands for CDH1 germline
mutations. In probands negative for CDH1, we have
screened the entire coding sequence and splice-sites of
several candidate genes, namely SMAD4, Caspase-10
and the mutational hotspots corresponding to exons 5–8
of p53. Whenever tumour tissue was available, we per-formed MSI analysis, and in MSI-positive cases hMLH1
and hMSH2 coding sequences were studied to exclude
HNPCC.2. Materials and methods
2.1. Patients
The study protocol was reviewed and approved by
the appropriate Ethics Committees and blood samples
and family histories were obtained with informed con-
sent. Thirty two families of Portuguese origin with a
positive history of gastric cancer and 23 early onset
gastric cancer patients (6 45 years old) were studied
(Table 1). Nine families fulfilled the IGCLC criteria for
HDGC. Ten families had an index case with diffuse
gastric cancer (FDGC). Three families had an index case
with intestinal gastric cancer (FIGC). Ten families had
aggregation of gastric cancer, but without histology
available (FGC). The nine HDGC families followed the
criteria of the IGCLC: (1) two or more documented
cases of diffuse gastric cancer in first-second-degree rel-
atives, with at least one diagnosed before the age of 50
years; or (2) three or more cases of documented diffuse
gastric cancer in first-second-degree relatives, indepen-
dent of their age. Sixteen early onset gastric cancer pa-
tients had diffuse type gastric carcinoma, two had
intestinal type carcinoma and five had developed gastric
cancer at an early age, but the histological classification
was unknown. Genomic DNA was isolated, using
standard methods, either from peripheral blood or from
frozen normal mucosa. In a few cases in which fresh
material was not available, DNA was isolated from
paraffin-embedded normal mucosa (germline muta-
tion screening) or tumour (MSI analysis) by phenol/
chloroform extraction, using standard methods, after
macrodissection.
2.2. Polymerase chain reaction–single-strand conforma-
tion polymorphism analysis (PCR-SSCP)
All coding regions from CDH1, intron–exon bound-
aries and the promoter region of the CDH1 gene were
amplified by polymerase chain reaction (PCR) from
germline DNA. Primer sequences and PCR conditions
were based on those previously reported in [17]. The
same approach was used to amplify SMAD4, p53 and
Caspase-10. Primers to amplify SMAD4 exons 1 and 10
were based on those previously reported in [18], and the
remaining exons were amplified with newly-designed
primers (primer sequences are given upon request). The
p53 mutational hotspot (exons 5–8), was amplified using
the primers from the Operon kit (Operon Technologies,
Inc. Atlantic City. CA, USA) following the manufac-
turer’s instructions. Caspase-10 genomic sequences were
Table 1
Germline mutations and sequence variants found in CDH1 and in other candidate genes in gastric cancer probands
Clinical criteria of
the families
n ¼ 32 Germline
mutations
Sequence variants Effect Frequency in
controls (%)
Refs.
HDGC 9 1/9 (11.1%) CDH1 1/9CDH1 1896C>T Silent 5 [12]
1/9 p53 639A>G Silent 11 [30]
1/9 Caspase-10 IVS5-
20C>T
Unknown 3.8 Present work
FDGC 10 0/10 2/10 CDH1 IVS1+6T>C Unknown 27 [12]
1/10 CDH1 IVS4+10G>C Unknown Nd [12]
1/10 CDH1 1896C>T Silent 5 [12]
1/10 CDH1 2253C>T Silent Nd [12]
1/10 SMAD4 IVS7-
31G>A
Unknown 1.1 Present work
FIGC 3 0/3 1/3 CDH1 IVS1+6T>C Unknown 27 [12]
1/3 Caspase-10 IVS5-
20C>T
Unknown 3.8 Present work
FGC 10 1/10 (10%) p53 3/10 CDH1 IVS1+6T>C Unknown 27 [12]
1/10 CDH1 IVS4+10G>C Unknown Nd [12]
1/10 Caspase-10 1217A>T Ile406Leu 3.4 Present work
1/10 SMAD4 1086T>C Silent 1.1 [22]
Early onset patients n ¼ 23
EODGC 16 0/16 2/16 CDH1 IVS1+6T>C Unknown 27 [12]
5/16 CDH1 IVS4+10G>C Unknown Nd [12]
2/16 CDH1 1896C>T Silent 5 [12]
1/16 CDH1 2253C>T Silent Nd [12]
1/16 Caspase-10 1217A>T Ile406Leu 3.4 Present work
1/16 SMAD4 IVS7-
31G>A
Unknown 1.1 Present work
EOIGC 2 0/2
EOGC 5 0/5 2/5 CDH1 IVS4+10G>C Unknown Nd [12]
HDGC, hereditary diffuse gastric cancer; FDGC, familial diffuse gastric cancer; FIGC, familial intestinal gastric cancer; FGC, familial gastric
cancer; EODGC, early onset diffuse gastric cancer; EOIGC, early onset intestinal gastric cancer; EOGC, early onset gastric cancer, Nd, not done.
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ously described in [16]. Genomic DNA (25–100 ng) was
amplified by PCR using the following cycling condi-
tions: 30 s at 94 C, 30 s at the appropriate annealing
temperature, and 45 s at 72 C for 35 cycles. Reaction
products were subsequently diluted 1:1 with denaturing
buffer (formamide with 0.025% xylene cyanol and
0.025% bromophenol blue) and heated up to 99 C for
10 min before being loaded onto 0.6 and 0.8 muta-
tion detection enhancement (MDE – Flowgen, Rock-
land, ME, USA) gels. Gels were run at constant
temperature for 12–8 h and stained with silver nitrate.
2.3. Sequencing analysis
Samples showing abnormal bands detected by single-
strand conformation polymorphism (SSCP) analysis,
were re-submitted to PCR and products were purified
and sequenced on an ABI Prism 377 automated se-
quencer (Perkin–Elmer) using the ABI prism dye ter-
minator cycle sequencing kit (Perkin–Elmer, Foster
City, CA, USA) and the original primers for bothstrands. All sequence alterations detected were con-
firmed in a second independent PCR.
2.4. Microsatellite instability analysis
Available neoplastic lesions from family probands
and early onset gastric cancer patients were studied for
MSI using a panel of 5 dinucleotide repeat markers and/
or BAT 26 [19]. The PCR products from tumour versus
constitutional DNA were labelled by [a32P] deoxycyt-
idine triphosphate (dCTP) during the amplification re-
action, separated by electrophoresis in 6% denaturing
polyacrylamide gels, at a constant current over ap-
proximately 3 h, and visualised by autoradiography.
2.5. DGGE
Germline mutational analysis of hMLH1 and
hMSH2 genes in family FGC#1 and FGC#24 which
had MSI gastric carcinoma in the proband, was per-
formed by denaturing gradient gel electrophoresis
(DGGE) as described in [20].
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Novel sequence variants detected were tested in at
least 156 chromosomes from Caucasian blood donors.3. Results
From the Portuguese families with an aggregation of
gastric cancer, one out of 32 (3.1%) harboured a germline
mutation in CDH1. This family (FGC#32) was one of
the nine (11.1%) kindred that fulfilled the criteria for
HDGC (Tables 1 and 2). The proband in this family was
heterozygous for a missense mutation at position 1901
(C>T) in codon 634, leading to an amino acid substitu-Table 2
Details of the two families with an aggregation of gastric cancer carrying ge
ID Clinical
criteria
Members
with GC
Genera-
tions
Mean age
(years old)
Age ran
(years o
FGC#11 FGC 3 2 38 26–52
FGC#32 HDGC 2 1 24.5 23–26
Fig. 1. Family pedigrees and mutation analysis from mutation-positive gas
gastric cancer (HDGC) family and sequencing analysis of the Ala634Val CD
Fraumeni kindred and sequencing analysis of the Arg158Gly p53 germline mu
the symbols; (+), Carriers of germline mutation; ()) Subjects that did not cation from Ala to Val (Fig. 1(a)). This germline mutation
was identified in DNA isolated from paraffin-embedded
normal tissue from the proband which developed an in-
vasive signet-ring carcinoma with few foci of in situ sig-
net-ring cancer at the age of 23 years. This patient had an
older brother who died four years before with diffuse
gastric carcinoma at the age of 26 years. However, no
good quality biological material was available from this
patient (only Holland Bouin fluid-fixed biopsies) to
search for the presence of the missense mutation
(Fig. 1(a)). These two siblings have six other brothers
and sisters who remain asymptomatic, as well as their
parents aged 63 and 65 years old, who refused any ge-
netic testing (Table 2, Fig. 1(a)). Twelve of the 31 re-
maining families and 11 of 23 early-onset cancer casesrmline mutations
ge
ld)
Cancers at
other sites
Germline
alteration
Exon Effect Cancer
syndrome
Colon,
pancreatic
p53
471C>G
5 Missense
Arg158-
Gly
Li-Frau-
meni
– CDH1
1901C>T
12 Missense
Ala634Val
HDGC
tric cancer families. (a) Pedigree from a Portuguese hereditary diffuse
H1 germline mutation in exon 12. (b) Pedigree from a Portuguese Li-
tation in exon 5. The age of onset of the tumours is shown underneath
rry the mutated alleles in the germline DNA; Arrow, Proband.
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phisms found are described in detail in Table 1.
Since most of our families were negative for CDH1,
we decided to screen for genes associated with other
cancer predisposing syndromes in which gastric cancer
also occurs. We screened p53 gene hotspots for germline
mutations (exons 5–8) where 95% of the p53 mutations
cluster [21]. One of the 10 families with familial aggre-
gation of gastric cancer (FGC) (FGC#11) harboured a
p53 germline missense mutation (Tables 1 and 2). This
mutation, occurring in p53 exon 5, was a heterozygous
C–G transversion at position 471, leading to an Arg–
Gly amino acid change at codon 158 (Table 2, Fig. 1(b)).
The proband was diagnosed with gastric carcinoma at
the age of 52 years, and had a family history of cancer.
Of the three proband’s offspring, one died at the age of
26 years with gastric cancer, the other died of an un-
determined cause, and the remaining offspring, who is
alive and healthy at the age of 33 years screened negative
for the p53 germline mutation. Two of the proband’s
three siblings died of cancer, one with gastric cancer at
the age of 36 years, and the other of colon cancer at the
age of 36 years. The proband’s father died at the age of
59 years with pancreatic cancer. No material was
available from the other affected members of the family.
In all probands negative for CDH1 and early onset
patients, we have also screened the entire coding se-
quence and splice-sites for SMAD4 and Caspase-10.
For SMAD4, two sequence variants were found, not
affecting the coding sequence. The first was an alteration
in intron 7 (IVS7-31G> A) of unknown significance and
not described previously, which was present in 1/10
FDGC and in 1/16 early onset diffuse gastric cancer pa-
tients. This sequence alteration was screened in a series of
94 blooddonors andone (1.1%) carried the same sequence
alteration (Table 1). The second was a silent polymor-
phism in exon 8, a transition (1086T>C) at codon 362
(Phe362Phe) previously described in the literature, and
was present in a FGC family [22]. As for the previous
sequence variant, the 1086T>C alteration was present in
1/94 (1.1%) of the blood donors analysed (Table 1).
The Caspase-10 mutation screening allowed the
identification of two new polymorphisms. The first, in
intron 5 (IVS5-20C>T) of unknown significance, was
present in two families (1/9 HDGC and 1/3 FIGC) and
in 3.8% of the 78 blood donors analysed (Table 1). The
second polymorphism detected, was a sequence alter-
ation in exon 9 (1217A>T) which changes the Ile406 for
a Leucine, and was found in 1/10 FGC and in 1/16 early
onset diffuse gastric cancer patients (Table 1). This se-
quence alteration was also screened in a series of 88
blood donors and three (3.4%) controls carried the same
sequence alteration, confirming its polymorphic nature
(Table 1).
In cases, in which tumour tissue was available, we
performed MSI analysis to exclude HNPCC. We wereable to analyse six of the 32 family tumours for MSI and
16 of 23 early onset gastric cancer patient tumours.
From the six family tumours, two showed MSI, whereas
none of the 16 tumours from early onset gastric cancer
patients presented with the MSI phenotype. The two
family probands carrying MSI tumours (FGC#1 and
FGC#24) were screened for mutations in hMLH1 and
hMSH2 by DGGE, but no germline mutations of these
two genes were found.4. Discussion
We have collected a series of 55 patients of Portu-
guese origin which developed gastric cancer, either with
a positive family history of gastric cancer or an early age
of onset. The sole CDH1 germline mutation found was
present in a family with HDGC. The CDH1 mutation
found in family FGC#32 is a missense mutation
(Ala634Val) and was identified in the 23 year old pro-
band. This mutation was shown to harbour dramatic
functional consequences in vitro [23]. Moreover, Vecsey-
Semjen and colleagues [24] found this same Ala634Val
mutation in a colon carcinoma cell line and showed that
this missense mutation results in the activation of a
cryptic splice-site, leading to a premature stop codon.
Both experiments support the pathogenic role of this
germline missense mutation. Interestingly, none of the
parents of the proband of family FGC#32 was affected
with gastric cancer, at the time of family history col-
lection, aged 65 and 63 years old. This suggests that
either the proband carries a de novo mutation in CDH1,
or that missense mutations in CDH1, although proved
as pathogenic, may have a lower penetrance in gastric
cancer families. The latter hypothesis seems more likely,
since the proband’s brother had gastric cancer of similar
histology, although a CDH1 study could not be carried
out in this patient. This is the first CDH1 germline
mutation described in a Portuguese HDGC family, and
represents a low percentage (11.1%) of HDGC families
carrying CDH1 mutations in comparison to the calcu-
lated percentage (33.0%) for all the HDGC families
studied to date [12]. Portugal is a high-risk country for
gastric carcinoma with an incidence of 37 new cases per
100 000 inhabitants per year [25]. This high incidence of
gastric cancer in Portugal in comparison to other
countries, and the low frequency of germline mutations
in high-penetrance genes, raises the possibility that
gastric cancer clustering observed in Portuguese families
may be related to low-penetrance predisposing genes in
association with environmental factors [26,27]. It should
be emphasised that the low frequency of CDH1 germline
mutations detect by us is not due to differing sensitivities
in our screening methodology (PCR/SSCP/sequencing),
since in most (if not all) published studies the methods
used were essentially the same [12].
1902 C. Oliveira et al. / European Journal of Cancer 40 (2004) 1897–1903In one of the 10 FGC kindred (FGC#11), we found a
p53 germline mutation, previously described in a Li-
Fraumeni kindred [28]. FGC#11 was clinically charac-
terised as a FGC family, since it had three members
affected with gastric cancer. This family also had a case
of pancreatic cancer and another case of colon cancer at
an early age, tumour types which have already been
described in HDGC families [12]. Li-Fraumeni syn-
drome is usually associated with a variety of different
tumour types occurring over a wide age range, including
in childhood. Although gastric, pancreatic and colon
cancers have been previously found in families with this
syndrome, paediatric tumours, such as osteosarcomas
and brain tumours, are typical tumours associated with
the Li-Fraumeni syndrome [8], which makes this family
an atypical Li-Fraumeni kindred with excess of gastric
cancer. Our results show that p53 mutations may be
involved in a percentage of families with an aggregation
of gastric cancer who lack CDH1 mutations.
We found that two of the families (FGC#1 and
FGC#24) carried tumours with MSI, raising the possi-
bility of a HNPCC syndrome. One of these families
(FGC#1) that fulfils the HDGC criteria, presented MSI
tumours in four affected family members, but no
germline mutations of hMSH2 and hMLH1 were found
[29]. However, in one of the patients the neoplastic le-
sion showed a lack of hMLH1 expression which was
found to be caused by hMLH1 promoter methylation,
suggesting the possibility of a sporadic tumour occur-
ring within this HDGC family [29]. In the other family
(FGC#24) with an aggregation of gastric cancer of un-
known histology, MSI was detected in the proband’s
tumour, but no germline mutations of hMLH1 or
hMSH2 were found.
In the remaining kindred without an underlying ge-
netic defect, other genes are probably involved. The
possibility of SMAD4 involvement in genetic predispo-
sition to diffuse gastric cancer was raised by the obser-
vation of foci of adenocarcinoma with signet-ring cells
in the stomach of heterozygous knock-out SMAD4 mice
[15]. Caspase-10 is another candidate gene for familial
gastric cancer, possibly through loss of apoptotic func-
tion, as suggested by reports of loss of heterozygosity
(LOH) and mutations in coding regions of this gene in
15% and 3%, respectively, of sporadic gastric cancer
cases [16]. From all of the probands screened in this
study, we identified sequence variants in SMAD4 and
Caspase-10. However, these sequence variants were ei-
ther silent or intronic, or a missense alteration that was
present with the same frequency as in normal controls
(Caspase-10 1217A>T), pointing to its polymorphic
nature. This observation suggests that these genes are
not important candidate genes in explaining the familial
gastric cancer cases.
In summary, we report the first CDH1 germline
mutation in Portuguese gastric cancer families. Fur-thermore, the present report highlights the need for p53
mutation screening in families with an excess of gastric
cancer and demonstrates that these p53 families should
have a distinct clinical follow-up. Finally, the two thirds
of HDGC families lacking CDH1 mutations seemed not
to be explained by germline mutations in SMAD4 and
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